Directory of funded grants

Filter by

552 results found

Novel biomarkers of SOD1 pathology in familial and sporadic ALS

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    Québec

  • Start Date

    2022

  • Total Grant Amount

    $125,000

  • Health Canada Contribution

    $62,500

Project Overview

Mutations in the SOD1 gene, leading to the misfolding and toxic aggregation of SOD1 protein, are the second leading cause of Familial Amyotrophic Lateral Sclerosis (FALS-SOD1) and emerging literature has detected misfolded SOD1 (mSOD1) in the cerebrospinal fluid (CSF) and post-mortem tissue of Sporadic ALS (SALS) patients. Based upon the…

Project Ongoing

See the project and researchers

Identification of Protein Interactions That Regulate FUS Mislocalization and Aggregation in ALS

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    Ontario

  • Start Date

    2022

  • Total Grant Amount

    $125,000

  • Health Canada Contribution

    $62,500

Project Overview

Amyotrophic lateral sclerosis (ALS) is a debilitating and terminal disease. A common hallmark of its familial and sporadic forms is the accumulation of insoluble protein aggregates in the cytoplasm of motor neurons. FUS RNA binding protein (FUS) is found in cytoplasmic protein aggregates of post-mortem spinal cords and brains in…

Project Ongoing

See the project and researchers

Imaging a New ALS Biomarker in the Eye

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    Ontario

  • Start Date

    2022

  • Total Grant Amount

    $125,000

  • Health Canada Contribution

    $62,500

Project Overview

Current biomarkers of ALS used by clinicians to help care for ALS patients have many drawbacks that may include cost, accessibility, and invasiveness of procedures. An imaging biomarker that is non-invasive, non-contact, and widely accessible would be a welcome addition to the current armamentarium of clinical tools used to diagnose,…

Project Ongoing

See the project and researchers

Effects of C9orf72 Deficiency on Inducing Neuronal Hyperexcitability In Vivo

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    Ontario

  • Start Date

    2022

  • Total Grant Amount

    $125,000

  • Health Canada Contribution

    $62,500

Project Overview

A G4C2 repeat expansion in C9orf72 (chromosome 9 open reading frame 72), a gene of unclear function, is the most frequent genetic cause of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (C9-ALS/FTD). The repeat expansions cause transcriptional downregulation of the C9orf72 mRNA resulting in loss of C9orf72 protein. As such…

Project Ongoing

See the project and researchers

Exploring the involvement of TDP-43 SUMOylation in ALS pathogenesis

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    Ontario

  • Start Date

    2022

  • Total Grant Amount

    $125,000

  • Health Canada Contribution

    $62,500

Project Overview

TDP-43 is an essential DNA/RNA binding protein at the epicenter of Amyotrophic Lateral Sclerosis (ALS). Nearly all cases of ALS present with TDP-43 pathology involving nuclear to cytoplasmic mislocalization and aggregation, however only a small subset of cases involve mutations in TDP-43. Therefore, it is critical to identify mechanisms regulating…

Project Ongoing

See the project and researchers